Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women

New England Journal of Medicine

Volumn 349, Issue 6, 2003, Pages 535-545

  Hodis, Howard N ^a,b,m   Mack, Wendy J ^a   Azen, Stanley P ^a   Lobo, Roger A ^c   Shoupe, Donna ^a   Mahrer, Peter R ^d   Faxon, David P ^e   Cashin Hemphill, Linda ^f   Sanmarco, Miguel E ^g   French, William J ^h   Shook, Thomas L ⁱ   Gaarder, Thomas D ^j   Mehra, Anilkumar O ^b   Rabbani, Ramin ^b   Sevanian, Alex ^a,b   Shil, Asit B ^a   Torres, Mina ^a   Vogelbach, K Heiner ^k   Selzer, Robert H ^a,l  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Kaiser Permanente Medical Center ^*  (United States)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Boston Heart Foundation   (United States)

^g Lakewood Regional Medical Center   (United States)

^h HARBOR UCLA MEDICAL CENTER   (United States)

ⁱ GOOD SAMARITAN HOSPITAL   (United States)

^j Presbyterian Intercommunity Hospital   (United States)

^k S California Heart Specialists   (United States)

^l CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^m Atherosclerosis Research Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; AGING; ANGIOCARDIOGRAPHY; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DEEP VEIN THROMBOSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; ENDOMETRIAL DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HORMONAL THERAPY; HUMAN; LIVER CIRRHOSIS; LUNG CANCER; LUNG EMBOLISM; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; UTERUS CANCER; DRUG COMBINATION; HORMONE SUBSTITUTION; MULTICENTER STUDY; PATIENT COMPLIANCE; TREATMENT FAILURE;

CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; PATIENT COMPLIANCE; POSTMENOPAUSE; TREATMENT FAILURE;

EID: 0042594633     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030830     Document Type: Article

References (37)

1. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
2. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208. [Erratum, JAMA 1995;274-1676.]
3. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
4. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
5. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8.
6. Byington RE, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692-7.
7. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
8. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
9. Kossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Hodis HN, Mack WJ, Lobo RA. What is the cardioprotective role of hormone replacement therapy? Curr Atheroscler Rep 2003;5:56-66.
11. Wei L-J. A class of designs for sequential clinical trials. J Am Stat Assoc 1977;72:382-6.
12. Blankenhorn DH, Johnson RL, Nessim SA, Azen SP, Sanmarco ME, Selzer RH. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987;8:356-87.
13. Cashin-Hemphill L, Kramsch DM, Azen SP, et al. The Monitored Atheroselerosis Regression Study (MARS): design, methods and base-line results. Online J Curr Clin Trials 1992 Oct. 23;Doc. No. 26. [Erratum, Online J Curr Clin Trials 1992 Nov. 14;Doc. No. 29.]
14. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40. [Erratum, JAMA 1988;259:2698.]
15. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MAPS). Ann Intern Med 1993;119:969-76.
16. Azen SP, Cashin-Hemphill L, Pogoda J, et al. Evaluation of human panelists in assessing coronary atherosclerosis. Arterioscler Thromb 1991;11:385-94.
17. Blankenhorn DH, Selzer RH, Mack WJ, et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effect. Circulation 1992;86:1701-9.
18. Selzer RH, Hagerty C, Azen SP, et al. Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical trials: a sampling study. J Clin Invest 1989;83:520-6.
19. The Lipid Research Clinics Program. Manual of laboratory operations. Vol. 1. Lipid and lipoprotein analysis. Bethesda, Md.: National Heart and Lung Institute, May 1974. (DHEW publication no. (NIH) 75-628.)
20. Viscoli CM, Brass LM, Kernan WN, Sartel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
21. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-62.
22. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for the prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-8.
23. Azen SP, Mack WJ, Cashin-Hemphill L, et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996;93:34-41.
24. Rosenfeld ME, Kauser K, Martin-McNulty B, Polinsky P, Schwartz SM, Rubanyi GM. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein B deficient mice. Atherosclerosis 2002;164:251-9.
25. Williams JK, Anthony MS, Honore EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 1995;15:827-36.
26. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
27. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-21.
28. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogen and soy phytoestrogens. J Clin Endocrinol Metab 2001;86:41-7.
29. Campisi R, Nathan L, Pampaloni MH, et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation 2002;105:425-30.
30. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
31. Post WS, Goldschmidt-Clermont PJ, Wilhide CC, et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999;43:985-91.
32. Espeland MA, Applegate WB, Furberg CD, Lefkowitz DS, Rice L, Hunninghake D. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995;142:1011-9.
33. Herrington DM, Vittinghoff E, Lin E, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-7.
34. Zanger D, Yang BK, Ardans J, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 2000;36:1797-802.
35. Galis ZS, Khatri JJ. Matrix metal loproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62.
36. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23-769-75.
37. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003;88:77-82.